WO2019109937A1 - Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途 - Google Patents
Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途 Download PDFInfo
- Publication number
- WO2019109937A1 WO2019109937A1 PCT/CN2018/119313 CN2018119313W WO2019109937A1 WO 2019109937 A1 WO2019109937 A1 WO 2019109937A1 CN 2018119313 W CN2018119313 W CN 2018119313W WO 2019109937 A1 WO2019109937 A1 WO 2019109937A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- pain
- cycloalkyl
- aryl
- alkyl
- Prior art date
Links
- 0 CC(C)C[C@](C(N[C@](C*)C(N1CC*CC1)=O)=O)NC([C@@](Cc1ccccc1)NC(CN(*)*)=O)=O Chemical compound CC(C)C[C@](C(N[C@](C*)C(N1CC*CC1)=O)=O)NC([C@@](Cc1ccccc1)NC(CN(*)*)=O)=O 0.000 description 3
- POGYITUWKDFDGK-AZGAKELHSA-N C(CN[C@@H](CC1)c2ccccc2C11OCCO1)[C@@]1(CC2(CCCC2)OCC1)c1ncccc1 Chemical compound C(CN[C@@H](CC1)c2ccccc2C11OCCO1)[C@@]1(CC2(CCCC2)OCC1)c1ncccc1 POGYITUWKDFDGK-AZGAKELHSA-N 0.000 description 1
- JMIONRUOFFQXRS-UNCTUWKVSA-N CCCO[C@@H](CC1)c2ccccc2[C@H]1NCC[C@@]1(CC2(CCCC2)OCC1)c1ncccc1 Chemical compound CCCO[C@@H](CC1)c2ccccc2[C@H]1NCC[C@@]1(CC2(CCCC2)OCC1)c1ncccc1 JMIONRUOFFQXRS-UNCTUWKVSA-N 0.000 description 1
- GGJFSIWVEDPXMA-SNHWACLSSA-N N#CCC(CC[C@@H]1NCC[C@@]2(CC3(CCCC3)OCC2)c2ncccc2)c2c1cccc2 Chemical compound N#CCC(CC[C@@H]1NCC[C@@]2(CC3(CCCC3)OCC2)c2ncccc2)c2c1cccc2 GGJFSIWVEDPXMA-SNHWACLSSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the invention belongs to the field of medicine and relates to the use of a KOR agonist in combination with a MOR agonist for the preparation of a medicament for relieving and/or treating pain.
- Pain refers to a person's functional or substantial feelings.
- the classification of pain is more complicated. According to the etiology classification, it is mainly divided into traumatic pain, pathological pain, pain caused by metabolic diseases, neuropathic pain, pain caused by tissue and organ malformation, psychological pain, and pain caused by compound factors. According to the course of disease, it can be divided into transient pain, acute pain and chronic pain. According to the degree of pain, it can be divided into slight pain, mild pain, very pain, and severe pain. According to the anatomy, it can be divided into headache and maxillofacial pain. Pillow pain, neck and shoulder pain, upper limb pain, chest pain, abdominal pain, low back pain; according to the location of the pain and causes, can be divided into peripheral pain, central pain, psychological pain.
- the causes of painful diseases are complex, and the symptoms are different.
- the degree of patient tolerance to pain and the response to treatment vary widely.
- the commonly used drugs for the treatment of pain mainly include anti-inflammatory analgesics and narcotic analgesics.
- drugs for analgesia there are still constipation, respiratory depression, sedation and lethargy, nausea and vomiting, acute poisoning, physical dependence and drug resistance, Problems such as spiritual dependence.
- Opioids are commonly used analgesics in clinical practice, especially in the treatment of patients with severe pain and advanced cancer, mainly through the action of opioid receptors to produce analgesic effects.
- Opioid receptors are members of the G-protein coupled receptor superfamily and participate in various physiological activities such as analgesia, inhibition of gastrointestinal motility, respiratory depression, myocardial protection, and immune response.
- Opioid receptors are generally considered to be classified into four subtypes: ⁇ opioid receptor (MOR), ⁇ opioid receptor (DOR), kappa opioid receptor (KOR), and opioid receptor-1 (ORL-1).
- MOR receptors have the strongest binding ability to morphin 1 , so the opioid analgesics used in clinical practice are mainly MOR agonists, including morphine, tramadol, fentanyl, oxycodone, etc., but long-term The use of this class of drugs can cause severe side effects such as analgesic tolerance, dependence and addiction.
- Phase III clinical MOR agonists are TRV-130 being developed by Trevena Inc.
- WO2017063509 discloses a novel MOR agonist whose structure is as follows:
- WO2012129495 discloses a structurally similar MOR agonist.
- KOR kinase C activity thereby inhibiting the analgesic tolerance and dependence of MOR agonists; CunhaTM et al. found that ([J]. Molecular pain, 2012, 8(1): 10) peripheral activation of KOR can inhibit inflammatory pain And activation of peripheral MOR can inhibit prostaglandin E2-induced progressive hyperalgesia. It has been reported that activation of KOR can also inhibit inflammatory hyperalgesia, and its mechanism may activate PI3K ⁇ /AKT signaling pathway through nNOS/NO signaling pathway; Liu Rong et al reported KOR agonist nalbuphine and MOR agonist sufentanil for postoperative analgesic sedation after total hip arthroplasty ([J]. China Pharmaceuticals, 2016, 25(22): 41-44), showing joint The analgesic effect of administration was better than that of single administration, and adverse reactions such as nausea and vomiting and itching of the skin were also significantly reduced.
- Patent application PCT/CN2017/087328 provides a novel KOR agonist that is extremely low in brain tissue, has little effect on the central nervous system, has little effect on serum sodium, is not easily addicted, and is more safe, its structure As follows:
- WO2008060552 discloses a structurally similar KOR agonist, and its use in combination with other opioid receptor agonists, NSAIDs, antidepressants for analgesia;
- WO2016073443 discloses a similar KOR agonist for the treatment of surgical pain Use of hard tissue pain;
- WO2008057608 discloses the use of a similar KOR agonist in combination with a MOR agonist to treat pain and reduce the dose of MOR agonist to reduce adverse reactions;
- WO2015065867 discloses a similar KOR agonist in MOR Use after agonist administration to reduce the vomiting effect of MOR agonists.
- the combination of a KOR agonist with a MOR agonist is a potential method for pain relief and/or treatment.
- the present invention provides the use of a novel KOR agonist in combination with a MOR agonist for the manufacture of a medicament for the relief and/or treatment of pain.
- the technical problem to be solved by the present invention is to provide a use of a KOR agonist in combination with a MOR agonist for the preparation of a medicament for alleviating and/or treating pain.
- the KOR agonist is selected from the group consisting of a compound of the formula (I), or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, or a mixture thereof a form, or a pharmaceutically acceptable salt thereof, wherein the compound of the formula (I) has the following structure:
- G is selected from the group consisting of O, -NR 4 and -CR 5 R 6 ;
- R 1 is selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, a halogenated alkyl group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, -OR 7 , -C (O) R 7 , -C(O)OR 7 , -S(O) m R 7 and -NR 8 R 9 , wherein the alkyl group, haloalkyl group, cycloalkyl group, heterocyclic group, aryl group and The heteroaryl group is optionally selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and hetero
- R 2 is selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, a halogenated alkyl group, a cycloalkyl group, a cycloalkylalkyl group, a heterocyclic group, a heterocyclic alkyl group, an aryl group, an arylalkyl group, a heteroaryl group, a hetero Arylalkyl, -OR 7 , -C(O)R 7 and -C(O)OR 7 wherein alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero
- the cycloalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl groups are optionally selected from the group consisting of alkyl, haloalkyl, halo, amino, nitro, cyano, hydroxy, alkoxy, haloalkyl Substituted by
- R 3 is selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, a halogenated alkyl group, a cycloalkyl group, a cycloalkylalkyl group, a heterocyclic group, a heterocyclic alkyl group, an aryl group, an arylalkyl group, a heteroaryl group, a hetero Arylalkyl, -OR 7 , -C(O)R 7 and -C(O)OR 7 wherein alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetero
- the cycloalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl groups are optionally selected from the group consisting of alkyl, haloalkyl, halo, amino, nitro, cyano, hydroxy, alkoxy, haloalkyl Substituted by
- R 4 is selected from the group consisting of a hydrogen atom, an alkyl group, a halogenated alkyl group, a cycloalkyl group, an alkoxy group, a hydroxyalkyl group, an amino group, a carboxylate group, a heterocyclic group, an aryl group, a heteroaryl group, -OR 7 , -C ( O) R 7 , -C(O)OR 7 , -S(O) m R 7 , -NR 8 R 9 and -NHC(O)NR 8 R 9 wherein the alkyl group, cycloalkyl group, hetero
- the cyclo, aryl and heteroaryl groups are optionally selected from the group consisting of alkyl, halogen, hydroxy, amino, carboxylate, nitro, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, Substituting one or more substituents in the aryl and heteroaryl groups
- R 5 and R 6 are each independently selected from a hydrogen atom, an alkyl group, an alkoxy group, a hydroxyalkyl group, a hydroxyl group, an amino group, a carboxylate group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, -OR 7 , —C(O)R 7 , —C(O)OR 7 , —S(O) m R 7 , —NR 8 R 9 and —NHC(O)NR 8 R 9 , wherein said alkyl group,
- the cycloalkyl, heterocyclyl, aryl and heteroaryl groups are optionally selected from the group consisting of alkyl, halogen, hydroxy, amino, carboxylate, nitro, cyano, alkoxy, hydroxyalkyl, cycloalkyl Substituting one or more substituents in a heterocyclic group, an aryl group, and a heteroary
- R 7 is selected from the group consisting of a hydrogen atom, an alkyl group, an amino group, an alkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group,
- the aryl and heteroaryl are optionally selected from the group consisting of alkyl, halo, hydroxy, amino, nitro, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl Substituted by one or more substituents;
- R 8 and R 9 are each independently selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, a hydroxyalkyl group, a hydroxyl group, an amino group, a carboxylate group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group.
- alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are optionally selected from the group consisting of alkyl, halogen, hydroxy, amino, carboxylate, nitro, cyano, alkoxy, hydroxyalkane Substituted by one or more substituents of a group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group;
- n 0, 1, or 2.
- the KOR agonist is selected from the group consisting of the compounds of the formula (I-A):
- R 2 and R 3 are as defined in the compound represented by the formula (I).
- the KOR agonist is selected from the group consisting of the compounds of the formula (I-B):
- G and R 2 are as defined in the compound represented by the formula (I).
- the KOR agonist is selected from the group consisting of the compounds of the formula (I-C):
- R 2 is as defined in the compound represented by the formula (I).
- the KOR agonist or a pharmaceutically acceptable salt thereof is selected from the group consisting of:
- the MOR agonist is selected from the group consisting of a compound represented by the formula (II) or a tautomer, a mesogen, a racemate, an enantiomer, and a diastereomer. Isomers or mixtures thereof, or a pharmaceutically acceptable salt thereof:
- Ring A is selected from the group consisting of a cycloalkyl group and a heterocyclic group
- R is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl are optionally selected from the group consisting of alkyl, haloalkyl, halo, amino, nitro, cyano, alkoxy, haloalkoxy, hydroxy Alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR 3 , -C(O)R 3 , -C(O)OR 3 , -S(O)mR 3 and -NR 4 R Substituting one or more substituents in 5 ;
- R 1 is the same or different and is each independently selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, a halogenated alkyl group, a halogen, an amino group, a nitro group, a hydroxyl group, a cyano group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group.
- alkyl group, haloalkyl group, cycloalkyl group, Heterocyclyl, aryl and heteroaryl are optionally selected from alkyl, haloalkyl, halo, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, hetero Substituting one or more substituents of a cyclic group, an aryl group, and a heteroaryl group;
- R 2 is the same or different and is each independently selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, a halogenated alkyl group, a halogen group, an amino group, a nitro group, a hydroxyl group, a cyano group, an oxo group, an alkenyl group, a cycloalkyl group, a heterocyclic ring.
- alkyl group, Alkoxy, alkenyl, haloalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally selected from the group consisting of a halogen atom, an alkyl group, a halogenated alkyl group, a halogen, an amino group, a nitro group, a cyano group, a hydroxyl group, Substituted with one or more substituents of alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
- the two R 2 together form a cycloalkyl or heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkane Substituted by one or more substituents of an oxy group, a haloalkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group;
- R 3 is selected from the group consisting of a hydrogen atom, an alkyl group, a halogenated alkyl group, an amino group, an alkoxy group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group, wherein the alkyl group, the cycloalkyl group And a heterocyclic group, an aryl group and a heteroaryl group are optionally selected from the group consisting of alkyl, halogen, hydroxy, amino, nitro, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and Substituting one or more substituents in the heteroaryl;
- R 4 and R 5 are each independently selected from the group consisting of a hydrogen atom, an alkyl group, an alkoxy group, a hydroxyalkyl group, a hydroxyl group, an amino group, a carboxylate group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group.
- alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are optionally selected from the group consisting of alkyl, halogen, hydroxy, amino, carboxylate, nitro, cyano, alkoxy, hydroxyalkane Substituted by one or more substituents of a group, a cycloalkyl group, a heterocyclic group, an aryl group, and a heteroaryl group;
- p, q are each independently 0, 1, 2, 3 or 4;
- n 0, 1, or 2.
- the MOR agonist is selected from the group consisting of a compound of the formula (II-B) or a tautomer thereof, a mesogen, a racemate, an enantiomer, a diastereomer Or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- R 1 , R 2 and p are as defined in the compound represented by the formula (II).
- the MOR agonist or a pharmaceutically acceptable salt thereof is selected from the group consisting of:
- the MOR agonist is selected from the group consisting of hydromorphone hydrochloride, morphine, oxycodone, buprenorphine, sufentanil, fentanyl, and fentanyl, and rifampicin.
- the KOR agonist and the MOR agonist have synergistic pharmacological effects for relieving and/or treating pain; preferably, the compound 5 or a pharmaceutically acceptable salt thereof and the compound 20 or pharmaceutically acceptable thereof
- the salt has a synergistic pharmacological effect of relieving and/or treating pain.
- a method of alleviating and/or treating pain comprising administering to a patient a KOR agonist salt and a MOR agonist as described above.
- the pain is selected from the group consisting of acute pain and chronic pain
- the chronic pain is selected from the group consisting of headache, maxillofacial pain, occipital pain, neck and shoulder pain, upper limb pain, chest pain, abdominal pain, Low back pain, genital pain, urinary tract pain, dysmenorrhea.
- the pain is selected from the group consisting of traumatic pain, inflammatory pain, ischemic pain, pain caused by metabolic diseases, neuropathic pain, pain caused by tissue and organ malformation, labor pain, malignancy Pain caused by proliferative diseases.
- the traumatic pain is selected from surgery-induced pain (eg, appendectomy, open colorectal surgery, hernia repair, prostatectomy, colonectomy, gastrectomy, splenectomy, Colectomy, colostomy, pelvicoscopy, tubal ligation, hysterectomy, post-operative pain due to vasectomy or cholecystectomy), pain after medical treatment (eg colonoscopy, cystoscopy, Hysteroscopy or pain after cervical or endometrial biopsy), fracture pain, burn pain, abdominal traumatic pain, spinal traumatic pain, chest traumatic pain, post-traumatic headache.
- surgery-induced pain eg, appendectomy, open colorectal surgery, hernia repair, prostatectomy, colonectomy, gastrectomy, splenectomy, Colectomy, colostomy, pelvicoscopy, tubal ligation, hysterectomy, post-operative pain due to vasectomy or cholecystectomy
- pain after medical treatment eg colonos
- the inflammatory pain is selected from the group consisting of inflammatory headache, tissue inflammatory pain (such as rheumatoid arthritis, rheumatoid arthritis, osteoarthritis), organ and glandular inflammatory pain (eg , gastroesophageal reflux disease, pancreatitis, acute pyelonephritis, ulcerative colitis, cholecystitis, cirrhosis, hepatic cyst, hepatitis, duodenal ulcer or gastric ulcer, esophagitis, gastritis, gastroenteritis, colon Inflammation, diverticulitis, intestinal obstruction, ovarian cysts, pelvic inflammatory disease, ulcer perforation, peritonitis, prostatitis, interstitial cystitis, vasculitic pain.
- tissue inflammatory pain such as rheumatoid arthritis, rheumatoid arthritis, osteoarthritis
- organ and glandular inflammatory pain eg , gastroesophageal reflux
- the ischemic pain is selected from the group consisting of ischemic headache, limb ischemic pain, tissue ischemic pain, organ and gland ischemic pain.
- the pain caused by the metabolic disease is selected from the group consisting of pain caused by gout and pain caused by diabetes.
- the neuropathic pain is selected from the group consisting of phantom limb pain, stump pain, burning neuralgia, postherpetic neuralgia, sympathetic-related pain, and pain caused by burning foot syndrome. , folic acid deficiency peripheral neuralgia, vitamin B12 deficiency peripheral neuralgia, vitamin B1 deficiency polyneuropathy, leprosy neuralgia.
- the pain caused by the malignant proliferative disease is selected from the group consisting of tumor-induced pain, including but not limited to leukemia, lymphoma, myeloma, breast cancer, lung cancer, esophageal cancer, gastric cancer, colon cancer, liver cancer, Pain caused by pancreatic cancer, head and neck cancer, kidney cancer, bladder cancer, prostate cancer, ovarian cancer, endometrial cancer, cervical cancer, osteosarcoma, soft tissue sarcoma, melanoma, and brain tumor.
- tumor-induced pain including but not limited to leukemia, lymphoma, myeloma, breast cancer, lung cancer, esophageal cancer, gastric cancer, colon cancer, liver cancer, Pain caused by pancreatic cancer, head and neck cancer, kidney cancer, bladder cancer, prostate cancer, ovarian cancer, endometrial cancer, cervical cancer, osteosarcoma, soft tissue sarcoma, melanoma, and brain tumor.
- the pain is selected from moderate to severe pain.
- the moderate to severe pain is selected from the group consisting of traumatic pain, labor pain, tumor-induced pain, and inflammatory pain.
- the moderate to severe pain is not suitable and/or insensitive to non-opioid analgesic drugs, weak opioid analgesics.
- the present invention provides the above KOR agonist in combination with the above MOR agonist as a medicament for alleviating and/or treating pain.
- the weight ratio of the KOR agonist to the MOR agonist ranges from 0.01 to 1000, selected from the group consisting of 1000/1, 750/1, 500/1, 400/1, 250/1, 200 /1, 100/1, 100/3, 90/1, 80/1, 75/1, 70/1, 60/1, 50/1, 40/1, 30/1, 30/7, 20/1 , 20/7, 20/3, 20/9, 25/1, 25/2, 25/3, 25/4, 25/6, 25/7, 25/8, 25/9, 25/18, 15 /1, 15/2, 15/4, 18/1, 18/5, 18/7, 14/1, 14/3, 14/5, 14/9, 12/1, 12/5, 12/7 , 10/1, 10/3, 10/7, 10/9, 9/1, 9/2, 9/4, 8/1, 8/3, 8/5, 7/1, 7/2, 7 /3, 7/4, 7/5, 7/6, 6/1, 6/5, 5/1, 5/2, 5/3, 5/4, 4/1, 4/3, 3/1 , 3
- the KOR agonist is administered in a dose of 0.001 to 250 mg, preferably from 0.001 mg, 0.002 mg, 0.003 mg, 0.004 mg, 0.005 mg, 0.006 mg, 0.007 mg, 0.008 mg, 0.009.
- Mg 0.01 mg, 0.02 mg, 0.03 mg, 0.05 mg, 0.15 mg, 0.2 mg, 0.25 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.75 mg, 0.8 mg, 0.9 mg, 1 mg, 1.25 mg, 1.5 Mg, 1.75 mg, 2 mg, 2.25 mg, 2.5 mg, 2.75 mg, 3 mg, 3.25 mg, 3.5 mg, 3.75 mg, 4 mg, 4.5 mg, 5 mg, 6 mg, 7 mg, 7.5 mg, 8 mg, 9 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 18 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 250 mg; the MOR agonist is administered at a dose of 0.001-50 mg, preferably from 0.001 mg, 0.002 mg, 0.003 mg, 0.004 mg, 0.005 mg, 0.006 mg, 0.007 mg, 0.008 mg, 0.009 mg, 0.01 mg, 0.
- the KOR agonist is selected from the compound 5 or a pharmaceutically acceptable salt thereof, and is administered at a dose of 0.001 to 20 mg, preferably from 0.005 mg, 0.01 mg, 0.03 mg, 0.05 mg.
- the MOR agonist is selected from the group consisting of Compound 20 or a pharmaceutically acceptable salt thereof, and is administered at a dose of 0.001 to 20 mg, preferably from 0.001 mg, 0.002 mg, 0.003 mg, 0.004 mg.
- the KOR agonist is administered at a dose of 0.01-500 ⁇ g/kg, preferably from 0.01 ⁇ g/kg, 0.05 ⁇ g/kg, 0.1 ⁇ g/kg, 0.2 ⁇ g/kg, 0.25 ⁇ g/ Kg, 0.3 ⁇ g/kg, 0.4 ⁇ g/kg, 0.5 ⁇ g/kg, 0.6 ⁇ g/kg, 0.7 ⁇ g/kg, 0.8 ⁇ g/kg, 0.9 ⁇ g/kg, 1 ⁇ g/kg, 2 ⁇ g/kg, 2.5 ⁇ g/kg, 3 ⁇ g/kg, 4 ⁇ g/kg, 5 ⁇ g/kg, 8 ⁇ g/kg, 10 ⁇ g/kg, 15 ⁇ g/kg, 20 ⁇ g/kg, 24 ⁇ g/kg, 25 ⁇ g/kg, 30 ⁇ g/kg, 40 ⁇ g/kg, 50 ⁇ g/kg, 60 ⁇ g/ Kg, 70 ⁇ g/kg, 75 ⁇ g/kg,
- the KOR agonist is selected from the group consisting of Compound 5 or a pharmaceutically acceptable salt thereof, at a dose of 0.01-150 ⁇ g/kg, preferably from 0.01 ⁇ g/kg, 0.05 ⁇ g/kg, 0.1 ⁇ g/kg.
- the MOR agonist is selected from the group consisting of Compound 20 or a pharmaceutically acceptable salt thereof, and is administered at a dose of 0.001 to 150 ⁇ g/kg, preferably from 0.003 ⁇ g/kg, 0.005 ⁇ g/kg, 0.01 ⁇ g/kg.
- the combined modes of administration of the present invention are selected from the group consisting of simultaneous administration, independent formulation and co-administration or independent formulation and sequential administration.
- the invention further relates to the use of a MOR agonist in combination with a KOR agonist for the preparation of amelioration and/or treatment of pain, wherein the KOR agonist is administered for a first time at a dose of 0.05-50 times the maintenance dose, said MOR agonist
- the first dose of the agent is 1-50 times the maintenance dose.
- the invention further relates to the use of a KOR agonist in combination with a MOR agonist for the preparation of amelioration and/or treatment of pain, wherein the frequency of administration of the KOR agonist is once a day, twice a day, three times a day, once a week. Second, once every three weeks, once a month, the frequency of MOR agonist administration is once a day, twice a day, three times a day, once a week, once every two weeks, once every three weeks, once a month.
- the combination further comprises optionally comprising a third component selected from the third component selected from the group consisting of an opioid, a glucocorticoid, a non-steroidal anti-inflammatory drug, and a topical component.
- a third component selected from the third component selected from the group consisting of an opioid, a glucocorticoid, a non-steroidal anti-inflammatory drug, and a topical component.
- the invention further relates to a pharmaceutical composition of a KOR agonist and a MOR agonist, comprising optionally one or more pharmaceutically acceptable carriers, excipients and/or diluents.
- the pharmaceutical composition can be formulated into any of the pharmaceutically acceptable dosage forms.
- a pharmaceutical preparation containing the active ingredient as a KOR agonist or a MOR agonist can be formulated into tablets, capsules, pills, granules, solutions, suspensions, syrups, injections (including injections, injections, etc.) Bacterial powder and concentrated solution for injection), suppository, inhalant or spray.
- the KOR agonist and MOR agonist pharmaceutical compositions of the invention may be administered alone or in combination with one or more therapeutic agents.
- KOR agonist and MOR agonist for the preparation of a medicament for the preparation and/or treatment of pain
- the KOR agonist and the MOR agonist may be administered orally, parenterally (including but not limited to It is administered in the form of subcutaneous injection, intravenous injection, or intraperitoneal injection.
- the components to be combined may be administered simultaneously or sequentially.
- the ingredients to be combined may also be administered in combination in the form of the same formulation or in separate separate formulations.
- the term "combination or combination” is a mode of administration comprising two or more drugs sequentially or simultaneously, and the term “simultaneously” means the same administration.
- Periodically administering a KOR agonist with a MOR agonist, or a KOR agonist with a MOR agonist and any other third component drug for example, within two days, within three days, within a week, within two weeks, within one month, two or two The above drugs.
- the so-called “sequential or sequential" administration includes the administration of a KOR agonist and a MOR agonist, or a KOR agonist and a MOR agonist, and any other third component drug, respectively, in different administration cycles.
- an "effective amount” as used herein includes an amount sufficient to ameliorate or prevent a symptom or condition of a medical condition.
- An effective amount also means an amount sufficient to allow or facilitate the diagnosis.
- An effective amount for a particular patient or veterinary subject can vary depending on factors such as the condition to be treated, the overall health of the patient, the route and dosage of the method of administration, and the severity of the side effects.
- An effective amount can be the maximum dose or dosing regimen that avoids significant side effects or toxic effects.
- hydroxyalkyl refers to an alkyl group substituted with a hydroxy group, wherein alkyl is as defined above.
- haloalkyl refers to an alkyl group substituted by one or more halogens, wherein alkyl is as defined above.
- hydroxy refers to an -OH group.
- halogen means fluoro, chloro, bromo or iodo.
- amino refers to -NH2.
- cyano refers to -CN.
- nitro refers to -NO 2 .
- carboxylic acid group refers to -C(O)OH.
- carboxylate group refers to -C(O)O(alkyl) or -C(O)O(cycloalkyl), wherein alkyl, cycloalkyl are as defined above.
- X is selected from A, B, or C
- X is selected from A, B, and C
- X is A, B, or C
- X is A, B, and C
- heterocyclic group optionally substituted by an alkyl group means that an alkyl group may be, but not necessarily, present, and the description includes the case where the heterocyclic group is substituted with an alkyl group and the case where the heterocyclic group is not substituted with an alkyl group.
- Substituted refers to one or more hydrogen atoms in the group, preferably up to 5, more preferably 1 to 3, hydrogen atoms, independently of each other, substituted by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art will be able to determine (by experiment or theory) substitutions that may or may not be possible without undue effort. For example, an amino group or a hydroxyl group having a free hydrogen may be unstable when combined with a carbon atom having an unsaturated (e.g., olefinic) bond.
- “Pharmaceutical composition” means a mixture comprising one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as physiological/pharmaceutically acceptable carriers. And excipients.
- the purpose of the pharmaceutical composition is to promote the administration of the organism, which facilitates the absorption of the active ingredient and thereby exerts biological activity.
- “Pharmaceutically acceptable salt” refers to a salt of a compound of the invention which is safe and effective for use in a mammal and which possesses the desired biological activity.
- alkyl refers to a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing from 1 to 20 carbon atoms, preferably an alkyl group having from 1 to 12 carbon atoms, more preferably from 1 to 6 carbons.
- the alkyl group of the atom is a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing from 1 to 20 carbon atoms, preferably an alkyl group having from 1 to 12 carbon atoms, more preferably from 1 to 6 carbons.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 - dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2 -methylhexyl, 3-methylhexyl, 4-methylhexyl,
- lower alkyl groups having from 1 to 6 carbon atoms, non-limiting examples including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl Base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethyl Butyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl Base, 2,3-dimethylbutyl and the like.
- the alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, preferably one or more of the following groups independently selected from the group consisting of an alkane Base, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, naphthenic An oxy group, a heterocycloalkoxy group, a cycloalkylthio group, a heterocycloalkylthio group, an oxo group, a carboxyl group or a carboxylate group.
- an alkane Base alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, hetero
- cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 carbon atoms, preferably from 3 to 12 carbon atoms, more preferably from 3 to 6 carbon atoms. One carbon atom, most preferably from 5 to 6 carbon atoms.
- Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene
- a polycycloalkyl group includes a spiro ring, a fused ring, and a cycloalkyl group.
- spirocycloalkyl refers to a polycyclic group that shares a carbon atom (referred to as a spiro atom) between 5 to 20 members of a single ring, which may contain one or more double bonds, but none of the rings have a fully conjugated ⁇ electronic system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- the spirocycloalkyl group is classified into a monospirocycloalkyl group, a bispirocycloalkyl group or a polyspirocycloalkyl group, preferably a monospirocycloalkyl group and a bispirocycloalkyl group, depending on the number of common spiro atoms between the rings.
- spirocycloalkyl groups include:
- fused cycloalkyl refers to 5 to 20 members, and each ring in the system shares an all-carbon polycyclic group of an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or Multiple double bonds, but none of the rings have a fully conjugated ⁇ -electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- fused cycloalkyl groups include:
- bridged cycloalkyl refers to an all-carbon polycyclic group of 5 to 20 members, any two rings sharing two carbon atoms which are not directly bonded, which may contain one or more double bonds, but none of the rings have complete Conjugate ⁇ -electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members. Depending on the number of constituent rings, it may be classified into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl group, preferably a bicyclic ring, a tricyclic ring or a tetracyclic ring, more preferably a bicyclic ring or a tricyclic ring.
- bridged cycloalkyl groups include:
- the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring to which the parent structure is attached is a cycloalkyl group, non-limiting examples include indanyl, tetrahydronaphthalene A benzocycloheptyl group or the like; preferably a phenylcyclopentyl group or a tetrahydronaphthyl group.
- the cycloalkyl group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio a heterocycloalkylthio group, an oxo group, a carboxyl group or a carboxylate group.
- heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 ring atoms wherein one or more ring atoms are selected from nitrogen, oxygen or S(O).
- a hetero atom of m (where m is an integer of 0 to 2), but excluding the ring moiety of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
- Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, Hydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl and the like are preferably tetrahydropyranyl, piperidinyl or pyrrolidinyl.
- Polycyclic heterocyclic groups include spiro, fused, and bridged heterocyclic groups.
- spiroheterocyclyl refers to a polycyclic heterocyclic group in which one atom (called a spiro atom) is shared between 5 to 20 members of a single ring, wherein one or more ring atoms are selected from nitrogen, oxygen or S (O). ) m (where m is an integer 0 to 2) heteroatoms, and the remaining ring atoms are carbon. It may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- the spiroheterocyclyl group is classified into a monospiroheterocyclic group, a dispiroheterocyclic group or a polyspirocyclic group according to the number of shared spiro atoms between the ring and the ring, and is preferably a monospiroheterocyclic group and a dispiroheterocyclic group. More preferably, it is 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6-membered monospiroheterocyclic group.
- Non-limiting examples of spiroheterocyclyl groups include:
- fused heterocyclyl refers to 5 to 20 members, and each ring in the system shares an adjacent pair of atomic polycyclic heterocyclic groups with other rings in the system, and one or more rings may contain one or more Double bond, but none of the rings have a fully conjugated ⁇ -electron system in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), and the remaining rings
- the atom is carbon. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- fused heterocyclic groups include:
- bridge heterocyclyl refers to a polycyclic heterocyclic group of 5 to 14 members, any two rings sharing two atoms which are not directly bonded, which may contain one or more double bonds, but none of the rings have a total A ⁇ -electron system of a yoke in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), the remaining ring atoms being carbon. It is preferably 6 to 14 members, more preferably 7 to 10 members.
- bridge heterocyclic groups include:
- the heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring to which the parent structure is attached is a heterocyclic group, non-limiting examples of which include:
- the heterocyclic group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio a heterocycloalkylthio group, an oxo group, a carboxyl group or a carboxylate group.
- aryl refers to a 6 to 14 membered all-carbon monocyclic or fused polycyclic ring (i.e., a ring sharing a pair of adjacent carbon atoms) having a conjugated ⁇ -electron system, preferably 6 to 10 members, more preferably 5 to 6 yuan, such as phenyl and naphthyl.
- the aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring to which the parent structure is attached is an aryl ring, non-limiting examples of which include:
- the aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle An alkylthio group, a carboxyl group or a carboxylate group.
- heteroaryl refers to a heteroaromatic system containing from 1 to 4 heteroatoms, from 5 to 14 ring atoms, wherein the heteroatoms are selected from the group consisting of oxygen, sulfur and nitrogen.
- the heteroaryl group is preferably 5 to 10 members, and has 1 to 3 hetero atoms; more preferably 5 or 6 members, and 1 to 2 hetero atoms; preferably, for example, imidazolyl, furyl, thienyl, thiazolyl, pyridyl
- the oxazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl and the like are preferably an imidazolyl group, a pyrazolyl or pyrimidinyl group, or a thiazolyl group; more preferably a pyrazolyl group.
- the heteroaryl ring may be fused to an aryl
- the heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio a heterocycloalkylthio group, a carboxyl group or a carboxylate group.
- alkoxy refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl is as defined above.
- alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
- the alkoxy group may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, fluorenyl, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio a heterocycloalkylthio group, a carboxyl group or a carboxylate group.
- amino protecting group refers to a group suitable for protecting (preventing) an amino group from chemical reaction, but which is easily removed after the end of the chemical reaction required elsewhere in the molecule.
- Typical representatives of these groups are unsubstituted or substituted acyl groups, unsubstituted or substituted allyl groups, aryl groups, aralkyloxymethyl groups, aralkyl groups or together with a nitrogen atom to form heterocyclic groups and salts.
- Non-limiting examples include tert-butoxycarbonyl (Boc), benzyloxycarbonyl, isobutoxycarbonyl, fluorenylmethoxycarbonyl (Fmoc), benzoyl, substituted benzoyl, butyryl, acetyl, tri Fluoroacetyl, ortho-dimethylimido (Pht), succinimidyl, maleimido, benzyl, allyloxycarbonyl and p-methoxybenzyl.
- Boc tert-butoxycarbonyl
- benzyloxycarbonyl isobutoxycarbonyl
- fluorenylmethoxycarbonyl Fmoc
- benzoyl substituted benzoyl
- butyryl acetyl
- tri Fluoroacetyl ortho-dimethylimido
- succinimidyl maleimido
- benzyl allyloxycarbonyl and p-methoxybenzyl.
- These groups may be optionally substituted with a benzyl group, an o-methylbenzyl group, a trityl group and a diphenylmethyl group substituted with a halogen, an alkyl group, an alkoxy group, a hydroxyl group, a nitro group, an acylamino group, an acyl group or the like. Substituted by one or more substituents.
- the amino protecting group is preferably t-butoxycarbonyl and fluorenylmethoxycarbonyl (Fmoc).
- the term "synergistic effect” includes additive effect, potentiating effect, and potentiating effect, and “synergistic effect” of the present invention includes, but is not limited to, reducing resistance when KOR agonist or MOR agonist is used alone. Symptoms, reduce the dose of KOR agonists, MOR agonists alone, reduce the adverse effects of KOR agonists, MOR agonists when used alone, enhance the use of the same dose of KOR agonists and / or the same dose of MOR agonists alone The effect of relieving and/or treating pain.
- acute pain refers to pain caused by harmful irritation caused by damage to skin, deep body structures or organs and/or diseases, or short-term pain caused by abnormal function of muscles or organs that do not cause actual tissue damage.
- chronic pain refers to a reasonable period of time beyond the usual course of the acute disease or the healing of the injury, or to a chronic pathological process that causes persistent pain, or pain that recurs at intervals of days, weeks, months, years; Chronic pain also includes the presence of pain if it should have been cured or after the usual course of treatment.
- inflammatory pain refers to local acute inflammation or chronic inflammation that stimulates nerve-induced pain.
- ischemic pain refers to pain caused by poor blood supply to the limb or organ.
- neuroopathic pain refers to pain caused by primary or secondary damage or dysfunction or transient disturbance of the surrounding or central nervous system.
- pain caused by malignant proliferative diseases refers to tumors caused by malignant proliferation of somatic cells, pain caused by cancer, pain caused by diseases caused by malignant proliferation of human organs, glands, blood system and skin, bacteria in human organs and glands The blood system and the malignant proliferation of the skin cause pain caused by the lesion.
- tissue refers to a population of cells that are identical in morphology or similar and functionally identical, including but not limited to epithelial tissue, connective tissue, muscle tissue, neural tissue, such as cartilage tissue, bone tissue, skeletal muscle, cardiac muscle, smooth muscle.
- Moderate to severe pain refers to severe pain that requires painkillers to relieve, painful treatments that affect disease treatment and/or vital signs, and effects that affect rehabilitation.
- first dose refers to the dose administered for the first time in the course of eliminating clinical symptoms and requiring continuous administration.
- maintenance dose refers to the amount used to consolidate and maintain a therapeutic effect after the clinical symptoms are controlled or alleviated.
- administered according to the need for pain refers to the administration of a mammalian self to the extent of pain perception for the purpose of relieving and/or treating pain.
- the meaning of the term "surgery” is not limited to the definition of a conventional surgery, which includes the contents of the classification according to the classification of the Department of Health of the Ministry of Health (2011 edition).
- the surgery described in the present invention encompasses at least one of the skin and the mucosa.
- Surgical incision, non-traditionally defined medical procedures eg, interventional procedures involving diagnosis and treatment).
- surgical-induced pain refers to a pain response after injury or stimulation of the tissue of the body, including preoperative, intraoperative, and postoperative pain during perioperative procedures, including but not limited to post-surgical pain ( For example, appendectomy, open colorectal surgery, hernia repair, prostatectomy, colonectomy, gastrectomy, splenectomy, colectomy, colostomy, pelvic laparotomy, tubal ligation, hysterectomy Postoperative pain caused by surgery, vasectomy or cholecystectomy), pain after medical treatment (eg colonoscopy, cystoscopy, hysteroscopy or pain after cervical or endometrial biopsy).
- post-surgical pain For example, appendectomy, open colorectal surgery, hernia repair, prostatectomy, colonectomy, gastrectomy, splenectomy, colectomy, colostomy, pelvic laparotomy, tubal ligation, hysterectomy
- tumor-induced pain refers to pain directly caused by a tumor, pain caused by tumor treatment, and pain caused by a tumor indirectly.
- Figure 1 is a graph showing the effect of a KOR agonist of the present invention in combination with a MOR agonist (Compound 5 and Compound 20) on the threshold of mechanical stimulation of the rat in a wound pain test.
- Compound 5 was determined by nuclear magnetic resonance (NMR) or/and mass spectrometry (MS).
- the NMR shift ( ⁇ ) is given in units of 10 -6 (ppm).
- NMR was measured using a Bruker AVANCE-400 nuclear magnetic apparatus, and the solvent was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated chloroform (CDCl 3 ), deuterated methanol (CD 3 OD), internal standard was four.
- DMSO-d 6 dimethyl sulfoxide
- CDCl 3 deuterated chloroform
- CD 3 OD deuterated methanol
- TMS Methyl silane
- the measurement of the MS was carried out using a FINNIGAN LCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQ advantage MAX).
- ESI FINNIGAN LCQAd
- Thin layer chromatography silica gel plate uses Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plate.
- the specification of silica gel plate used for thin layer chromatography (TLC) is 0.15mm ⁇ 0.2mm.
- the specification for thin layer chromatography separation and purification is 0.4mm. ⁇ 0.5mm.
- the known starting materials of the present invention may be synthesized by or according to methods known in the art, or may be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, Dari Companies such as chemicals.
- the solution means an aqueous solution.
- reaction temperature is room temperature and is 20 ° C to 30 ° C.
- the progress of the reaction in the examples was monitored by thin layer chromatography (TLC).
- TLC thin layer chromatography
- the system used for the reaction was: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether And the ethyl acetate system, D: acetone, the volume ratio of the solvent is adjusted depending on the polarity of the compound.
- Purification compounds using column chromatography eluent systems and thin layer chromatography developer systems include: A: dichloromethane and methanol systems, B: n-hexane and ethyl acetate systems, C: dichloromethane and acetone
- A dichloromethane and methanol systems
- B n-hexane and ethyl acetate systems
- C dichloromethane and acetone
- the volume ratio of the solvent is adjusted depending on the polarity of the compound, and a small amount of an alkaline or acidic reagent such as triethylamine or acetic acid may be added for adjustment.
- the high-pressure liquid chromatography used in the high performance liquid chromatography in the examples was (Gilson-281), the column was Shim-pack PREP-ODS of Shimadzu, and the mobile phase used was a trifluoroacetic acid buffer system, namely water ( Containing 0.05% trifluoroacetate)-acetonitrile.
- each of the compounds in the form of a trifluoroacetate salt in the examples can be obtained in a free state by the following general method: the trifluoroacetate salt is dissolved in a suitable solvent (e.g., methanol, ethanol, tetrahydrofuran, acetone, etc.), and a weak base is added. (such as sodium bicarbonate, sodium carbonate, potassium carbonate, etc.) adjust the pH to neutrality, concentrate under reduced pressure, and purify the residue to give a free state.
- a suitable solvent e.g., methanol, ethanol, tetrahydrofuran, acetone, etc.
- a weak base such as sodium bicarbonate, sodium carbonate, potassium carbonate, etc.
- the crude product 5f (60 mg, 0.066 mmol) was dissolved in dichloromethane (2 mL), and 1 mL of 4M hydrogen chloride in 1,4-dioxane solution was added, and the reaction was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced vacuo.
- Example 1 The apparatus, equipment and materials required for the preparation of the compound 20 are shown in Example 1.
- the reaction mixture was washed with EtOAcqqqqqqHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
- the crude compound 19a (698 mg, 2.4 mmol) was dissolved in 4 mL of dichloromethane, and 8 mL of 4M hydrogen chloride in 1,4-dioxane solution was added, and the reaction was stirred for 2 hours.
- Example 3 Effect of the KOR agonist of the present invention in combination with a MOR agonist on the treatment of incisional pain in rats
- Wistar male rats were purchased from Shanghai Slack Laboratory Animal Co., Ltd., purchased at 140-160g/head, 5/cage, 12/12 hour light/dark cycle adjustment, temperature 23 ⁇ 1°C constant temperature, humidity 50 to 60%, free to eat into the water. After the animals were purchased, the experiment was started after adaptive feeding for more than 3 days.
- Electronic tactile measuring instrument (electronic Von Frey): UGO BASILE, model 38450.
- Both Compound 5 and Compound 20 were prepared using physiological saline.
- the model group and the drug-administered group were subjected to incision surgery. After anesthesia with isoflurane during surgery, a 1 cm long incision was made in the middle of the left hind paw with a surgical blade No.
- Experimental data is expressed as mean (Mean) ⁇ standard deviation (S.D.). Statistical comparisons were performed using the excel software t test. Comparing the model group with the blank control group data, whether there is significant statistical significance, #P ⁇ 0.05 indicates that the model group has significant difference compared with the blank control group, ##P ⁇ 0.01 indicates that the model group has a comparison with the blank control group. Highly significant differences. ⁇ P ⁇ 0.05 indicates that there is a significant difference between the test group and the model group, and ⁇ P ⁇ 0.01 indicates that the test group has a highly significant difference compared with the model group. *P ⁇ 0.05 indicates that there was a significant difference between the drug combination group and the single use group, and **P ⁇ 0.01 indicates that the drug combination group had a highly significant difference compared with the single use group.
- the threshold of the normal control group was 14.48 g
- the threshold of the model group was 8.91 g.
- the threshold of the model group decreased significantly ( P ⁇ 0.05);
- the compound 20-0.03 mg/kg group significantly increased the tenderness threshold of the rats (P ⁇ 0.01), reaching 14.46 g, with an increase of 62.3%; compound 5-0.3
- the mg/kg group significantly increased the tender threshold of the rats (P ⁇ 0.01), reaching 17.92 g, with an increase of 101.1%.
- the compound 20-0.03mg/kg combined with the compound 5-0.1mg/kg, the compound 5-0.3mg/kg, and the compound 5-1mg/kg can significantly increase the tenderness threshold of the rats.
- the ratios of 17.96g, 22.29g and 33.46 were increased by 101.6%, 150.1% and 275.5% (P ⁇ 0.01), respectively, reflecting the dose-effect relationship of KOR agonists.
- the efficacy of the three doses was better than that of the single compound 20-0.03 mg/kg, which was statistically different from the compound 5-0.3 mg/kg and the compound 5-1 mg/kg (P ⁇ 0.01).
- Compound 20-0.03 mg/kg+ compound 5-0.1 mg/kg is equivalent to the increase of pain threshold compared with 5-0.3 mg/kg of compound alone; compound 20-0.03 mg/kg combined with compound 5-0.3 mg/kg The compound 5-1 mg/kg was superior to the single compound 5-0.3 mg/kg, and the combined compound 5-1 mg/kg was statistically different (p ⁇ 0.01).
- the compounds 20-0.03 mg / kg and the compound 5-0.3 mg / kg were given to rats with good inhibition of incisional pain (P ⁇ 0.01); in addition, the test results of the combined drug group showed Compound 20 has a synergistic effect with Compound 5, and its combined efficacy is superior to the same dose alone.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (14)
- 一种κ阿片受体(KOR)激动剂与μ阿片受体(MOR)激动剂联合在制备缓解和/或治疗疼痛的药物中的用途,其特征在于,所述KOR激动剂选自如通式(I)所示化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其混合物形式,或其可药用的盐,其中:G选自O、-NR 4和-CR 5R 6;R 1选自氢原子、烷基、烷氧基、卤代烷基、卤素、氨基、硝基、羟基、氰基、环烷基、杂环基、芳基、杂芳基、-OR 7、-C(O)R 7、-C(O)OR 7、-S(O) mR 7和-NR 8R 9,其中所述的烷基、卤代烷基、环烷基、杂环基、芳基和杂芳基任选被选自烷基、卤代烷基、卤素、氨基、硝基、氰基、羟基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;R 2选自氢原子、烷基、烷氧基、卤代烷基、环烷基、环烷基烷基、杂环基、杂环基烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、-OR 7、-C(O)R 7和-C(O)OR 7,其中所述的烷基、卤代烷基、环烷基、环烷基烷基、杂环基、杂环基烷基、芳基、芳基烷基、杂芳基和杂芳基烷基任选被选自烷基、卤代烷基、卤素、氨基、硝基、氰基、羟基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;R 3选自氢原子、烷基、烷氧基、卤代烷基、环烷基、环烷基烷基、杂环基、杂环基烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、-OR 7、-C(O)R 7和-C(O)OR 7,其中所述的烷基、卤代烷基、环烷基、环烷基烷基、杂环基、杂环基烷基、芳基、芳基烷基、杂芳基和杂芳基烷基任选被选自烷基、卤代烷基、卤素、氨基、硝基、氰基、羟基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;R 4选自氢原子、烷基、卤代烷基、环烷基、烷氧基、羟烷基、氨基、羧酸酯基、杂环基、芳基、杂芳基、-OR 7、-C(O)R 7、-C(O)OR 7、-S(O) mR 7、-NR 8R 9和-NHC(O)NR 8R 9,其中所述的烷基、环烷基、杂环基、芳基和杂芳基任选被选自烷基、卤素、羟基、氨基、羧酸酯基、硝基、氰基、烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;R 5和R 6各自独立地选自氢原子、烷基、烷氧基、羟烷基、羟基、氨基、羧酸酯基、环烷基、杂环基、芳基、杂芳基、-OR 7、-C(O)R 7、-C(O)OR 7、-S(O) mR 7、-NR 8R 9和-NHC(O)NR 8R 9,其中所述的烷基、环烷基、杂环基、芳基和杂芳基任选被选自烷基、卤素、羟基、氨基、羧酸酯基、硝基、氰基、烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;R 7选自氢原子、烷基、氨基、烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基,其中所述的烷基、环烷基、杂环基、芳基和杂芳基任选被选自烷基、卤素、羟基、氨基、硝基、氰基、烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;R 8和R 9各自独立地选自氢原子、烷基、烷氧基、羟烷基、羟基、氨基、羧酸酯基、环烷基、杂环基、芳基和杂芳基,其中所述的烷基、环烷基、杂环基、芳基和杂芳基任选被选自烷基、卤素、羟基、氨基、羧酸酯基、硝基、氰基、烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;m为0、1或2。
- 如权利要求1-4任一项所述的用途,其特征在于,所述MOR激动剂选自如通式(II)所示化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其混合物形式,或其可药用的盐:其中:环A选自环烷基和杂环基;R选自芳基和杂芳基,其中所述的芳基和杂芳基任选被选自烷基、卤代烷基、卤素、氨基、硝基、氰基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基、杂芳基、-OR 3、-C(O)R 3、-C(O)OR 3、-S(O)mR 3和-NR 4R 5中的一个或多个取代基所取代;R 1相同或不同,且各自独立地选自氢原子、烷基、烷氧基、卤代烷基、卤素、氨基、硝基、羟基、氰基、环烷基、杂环基、芳基、杂芳基、-OR 3、-C(O)R 3、-C(O)OR 3、-S(O)mR 3和-NR 4R 5,其中所述的烷基、卤代烷基、环烷基、杂环基、芳基和杂芳基任选被选自烷基、卤代烷基、卤素、氨基、硝基、氰基、羟基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;R 2相同或不同,且各自独立地选自氢原子、烷基、烷氧基、卤代烷基、卤素、氨基、硝基、羟基、氰基、氧代基、烯基、环烷基、杂环基、芳基、杂芳基、-OR 3、-C(O)R 3、-C(O)OR 3、-S(O)mR 3和-NR 4R 5,其中所述的烷基、烷氧基、烯基、卤代烷基、环烷基、杂环基、芳基和杂芳基任选被选自氘原子、烷基、卤代烷基、卤素、氨基、硝基、氰基、羟基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;或者两个R 2一起形成环烷基或杂环基,其中所述的环烷基或杂环基任选被选自烷基、卤代烷基、卤素、氨基、硝基、氰基、羟基、烷氧基、卤代烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;R 3选自氢原子、烷基、氘代烷基、氨基、烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基,其中所述的烷基、环烷基、杂环基、芳基和杂芳基任选被选自烷基、卤素、羟基、氨基、硝基、氰基、烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;R 4和R 5各自独立地选自氢原子、烷基、烷氧基、羟烷基、羟基、氨基、羧酸酯基、环烷基、杂环基、芳基和杂芳基,其中所述的烷基、环烷基、杂环基、芳基和杂芳基任选被选自烷基、卤素、羟基、氨基、羧酸酯基、硝基、氰基、烷氧基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;p、q各自独立地为0、1、2、3或4;且m为0、1或2。
- 如权利要求1-4任一项所述的用途,其特征在于,所述MOR激动剂选自盐酸二氢吗啡酮、吗啡、羟考酮、丁丙诺啡、舒芬太尼、芬太尼、曲芬太尼、瑞芬太尼、他喷他多、NKTR-181、艾沙度林、苯并氢可酮、洛哌丁胺、oliceridine、samidorphan、cebranopadol、他喷他多、美沙酮、曲马朵、TV-46763、氢可酮、dexketoprofen、羟吗啡酮、MH-200、左啡诺、Sedatin、去甲基曲马多、IBCh-07、HS-731、Cyt-1010、曲美布汀3-硫代氨基甲酰基-苯磺酸盐、thienorphine、trimebutine、TRV-734、TRK-130、氢吗啡酮、氢吗啡酮前药、EU-178、OREX-1038、AIKO-152、TH-030418、CC-408、XE-440、CYX-6、Org-41793、DPI-125、KN-203、JVA-3025、suboxone、AT-121、VRP-26、内吗啡肽、NKTR-196、NKTR-174、NKTR-192、NESS-117-OPB、SYK-524、HS-731、HS-198、Dmt-Tic类似物、内啡肽1衍生物、MMP-2200、SEO-16、TLI-0326、BU-08028、BU-08073、TLI-1186、KIN-3031、Neo-1509、GRT-6006、MCP-201、NE-2、MGM-9、EN-3231、NRP-290、NS-7051、CDS-PM-101、frakefamide、BCH-2687、SS-620、VANH-36、443C81、OHM-329、皮啡肽四肽类似物、sameridine、OHM-3507、SEP-130551、BW-2378W92、sulfazocine、Z-4349、RP-63494、BCH-150、CP-840、CP-0719。
- 如权利要求1的用途,其特征在于,所述的疼痛选自急性疼痛、慢性疼痛,所述的慢性疼痛选自头痛、颌面部痛、项枕部疼痛、颈肩痛、上肢痛、胸部痛、腹痛、腰腿痛、生殖道疼痛、泌尿道疼痛、痛经。
- 如权利要求1所述的用途,其特征在于,所述疼痛选自创伤性疼痛、炎性疼痛、缺血性疼痛、代谢性疾病引起的疼痛、神经源性疼痛、组织及器官畸形引起的疼痛、分娩疼痛、恶性增殖疾病引起的疼痛,所述的创伤性疼痛选自手术引起的疼痛、骨折疼痛、烧伤性疼痛、腹部外伤性疼痛、脊柱外伤性疼痛、胸部外伤性疼痛、外伤后头痛;所述的炎性疼痛选自炎性头痛、组织炎性疼痛、器官及腺体炎性疼痛、血管炎性疼痛;所述的缺血性疼痛选自缺血性头痛、肢体缺血性疼痛、组织缺血性疼痛、器官及腺体缺血性疼痛;所述的代谢性疾病引起的疼痛选自痛风引起的疼痛、糖尿病引起的疼痛;所述的神经源性疼痛选自幻肢痛、残端痛、灼性神经痛、带状疱疹后遗神经痛、交感神经相关性疼痛、灼热足综合征引发的疼痛、叶酸缺乏性周围神经痛、维生素B12缺乏性周围神经痛、维生素B1缺乏性多发性神经、麻风病性神经痛;所述的恶性增殖疾病引起的疼痛选自肿瘤引起的疼痛,优选为白血病、淋巴瘤、骨髓瘤、乳腺癌、肺癌、食管癌、胃癌、大肠癌、肝癌、胰腺癌、头颈部癌、肾癌、膀胱癌、前列腺癌、卵巢癌、子宫内膜癌、子宫颈癌、骨肉瘤、软组织肉瘤、黑色素瘤、脑瘤引起的疼痛。
- 如权利要求10所述的用途,其特征在于,所述的疼痛选自中至重度疼痛,优选自创伤性疼痛、分娩疼痛、肿瘤引起的疼痛、炎性疼痛。
- 如权利要求11所述的用途,其特征在于,所述的中至重度疼痛对非阿片类镇痛药物、弱阿片类镇痛药物不适用和/或不敏感。
- 如有权利要求1所述的用途,其特征在于,所述联合还包含第三组分,所述第三组分选自阿片类药物、糖皮质激素、非甾体抗炎药、麻醉药、局部麻醉药、抗抑郁药、钙离子通道拮抗剂、抗惊厥药物、肾上腺β受体阻断剂、麻醉诱导剂。
- 一种药物组合物,含有权利要求1-8任一项所述的MOR激动剂或其可药用盐与KOR激动剂或其可药用盐,以及一种或多种可药用的赋型剂、稀释剂或载 体。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18885338.6A EP3714882A4 (en) | 2017-12-06 | 2018-12-05 | USE OF A KOR AGONIST IN COMBINATION WITH A MOR AGONIST IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PAIN |
CN201880059072.XA CN111065390B (zh) | 2017-12-06 | 2018-12-05 | Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途 |
CA3083028A CA3083028A1 (en) | 2017-12-06 | 2018-12-05 | Use of kor agonist in combination with mor agonist in preparing drug for treating pain |
AU2018380173A AU2018380173A1 (en) | 2017-12-06 | 2018-12-05 | Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain |
KR1020207018160A KR20200096787A (ko) | 2017-12-06 | 2018-12-05 | 통증을 치료하는 약물의 제조에 있어서의 kor 작용제 및 mor 작용제의 조합의 용도 |
RU2020115687A RU2776842C2 (ru) | 2017-12-06 | 2018-12-05 | Применение агониста kor в комбинации с агонистом mor для получения лекарственного средства для лечения боли |
MX2020005660A MX2020005660A (es) | 2017-12-06 | 2018-12-05 | Uso de un agonista de kor en combinacion con un agonista de mor para preparar medicamentos para tratar el dolor. |
BR112020010429-9A BR112020010429A2 (pt) | 2017-12-06 | 2018-12-05 | uso de agonista de kor em combinação com agonista de mor na preparação de fármaco para tratamento da dor |
US16/767,523 US11471503B2 (en) | 2017-12-06 | 2018-12-05 | Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain |
JP2020529356A JP2021505547A (ja) | 2017-12-06 | 2018-12-05 | 疼痛を治療するための薬物の製造におけるmorアゴニストと組み合わせたkorアゴニストの使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711272869 | 2017-12-06 | ||
CN201711272869.1 | 2017-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019109937A1 true WO2019109937A1 (zh) | 2019-06-13 |
Family
ID=66751289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/119313 WO2019109937A1 (zh) | 2017-12-06 | 2018-12-05 | Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11471503B2 (zh) |
EP (1) | EP3714882A4 (zh) |
JP (1) | JP2021505547A (zh) |
KR (1) | KR20200096787A (zh) |
CN (1) | CN111065390B (zh) |
AU (1) | AU2018380173A1 (zh) |
BR (1) | BR112020010429A2 (zh) |
CA (1) | CA3083028A1 (zh) |
MX (1) | MX2020005660A (zh) |
TW (1) | TW201924681A (zh) |
WO (1) | WO2019109937A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020147848A1 (zh) * | 2019-01-17 | 2020-07-23 | 上海海雁医药科技有限公司 | 三环取代的氧杂螺环衍生物、其制法与医药上的用途 |
CN113493490A (zh) * | 2020-04-03 | 2021-10-12 | 成都诺和晟泰生物科技有限公司 | 一种合成肽酰胺类化合物及其在医药领域的用途 |
CN113995733A (zh) * | 2021-09-18 | 2022-02-01 | 中国人民解放军军事科学院军事医学研究院 | 一种噻吩诺啡缓释药物组合物及其制备方法和其用途 |
US11492374B2 (en) | 2020-06-25 | 2022-11-08 | Humanwell Pharmaceutical US | Peptides for treatment of medical disorders |
CN115317453A (zh) * | 2022-09-01 | 2022-11-11 | 广东嘉博制药有限公司 | 一种缓释微球制剂及其制备方法与用途 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109982699A (zh) * | 2017-04-14 | 2019-07-05 | 江苏恒瑞医药股份有限公司 | 一种mor激动剂与kor激动剂的药物组合物及其用途 |
US20230096978A1 (en) * | 2020-08-10 | 2023-03-30 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Mor receptor agonist compound, preparation method therefor, and use thereof |
CN112694485B (zh) * | 2020-09-10 | 2023-04-07 | 四川海品信医药科技有限公司 | 一种阿片受体激动剂噻吩类化合物及其制备方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008057608A2 (en) | 2006-11-10 | 2008-05-15 | Cara Therapeutics, Inc. | Synthetic peptide amides |
WO2008060552A2 (en) | 2006-11-10 | 2008-05-22 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimers thereof |
US20110212882A1 (en) | 2006-11-10 | 2011-09-01 | Cara Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
WO2012129495A1 (en) | 2011-03-23 | 2012-09-27 | Trevena, Inc. | Opioid receptor ligands and methods of using and making same |
CN104271552A (zh) * | 2012-03-05 | 2015-01-07 | 雷迪博士实验室有限公司 | 作为kappa阿片样物质受体(kor)激动剂的取代的杂环乙酰胺 |
WO2015065867A2 (en) | 2013-10-28 | 2015-05-07 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting |
WO2016073443A2 (en) | 2014-11-05 | 2016-05-12 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for hard tissue pain |
WO2017063509A1 (zh) | 2015-10-15 | 2017-04-20 | 江苏恒瑞医药股份有限公司 | 氧杂螺环类衍生物、其制备方法及其在医药上的应用 |
WO2017211272A1 (zh) * | 2016-06-07 | 2017-12-14 | 江苏恒瑞医药股份有限公司 | 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用 |
WO2018103624A1 (zh) * | 2016-12-06 | 2018-06-14 | 江苏恒瑞医药股份有限公司 | 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109982699A (zh) * | 2017-04-14 | 2019-07-05 | 江苏恒瑞医药股份有限公司 | 一种mor激动剂与kor激动剂的药物组合物及其用途 |
-
2018
- 2018-12-05 BR BR112020010429-9A patent/BR112020010429A2/pt not_active Application Discontinuation
- 2018-12-05 KR KR1020207018160A patent/KR20200096787A/ko active Search and Examination
- 2018-12-05 CA CA3083028A patent/CA3083028A1/en active Pending
- 2018-12-05 WO PCT/CN2018/119313 patent/WO2019109937A1/zh active Application Filing
- 2018-12-05 US US16/767,523 patent/US11471503B2/en active Active
- 2018-12-05 JP JP2020529356A patent/JP2021505547A/ja active Pending
- 2018-12-05 EP EP18885338.6A patent/EP3714882A4/en not_active Withdrawn
- 2018-12-05 TW TW107143659A patent/TW201924681A/zh unknown
- 2018-12-05 MX MX2020005660A patent/MX2020005660A/es unknown
- 2018-12-05 AU AU2018380173A patent/AU2018380173A1/en not_active Abandoned
- 2018-12-05 CN CN201880059072.XA patent/CN111065390B/zh active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008057608A2 (en) | 2006-11-10 | 2008-05-15 | Cara Therapeutics, Inc. | Synthetic peptide amides |
WO2008060552A2 (en) | 2006-11-10 | 2008-05-22 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimers thereof |
US20110212882A1 (en) | 2006-11-10 | 2011-09-01 | Cara Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
WO2012129495A1 (en) | 2011-03-23 | 2012-09-27 | Trevena, Inc. | Opioid receptor ligands and methods of using and making same |
CN103702561A (zh) * | 2011-03-23 | 2014-04-02 | 特维娜有限公司 | 阿片样物质受体配体以及使用和制备其的方法 |
CN104271552A (zh) * | 2012-03-05 | 2015-01-07 | 雷迪博士实验室有限公司 | 作为kappa阿片样物质受体(kor)激动剂的取代的杂环乙酰胺 |
WO2015065867A2 (en) | 2013-10-28 | 2015-05-07 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting |
TW201601743A (zh) * | 2013-10-28 | 2016-01-16 | 卡拉治療股份有限公司 | 外周kappa鴉片受體促進劑用於製備預防、抑制或治療噁心及嘔吐之藥物的用途 |
WO2016073443A2 (en) | 2014-11-05 | 2016-05-12 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for hard tissue pain |
WO2017063509A1 (zh) | 2015-10-15 | 2017-04-20 | 江苏恒瑞医药股份有限公司 | 氧杂螺环类衍生物、其制备方法及其在医药上的应用 |
WO2017211272A1 (zh) * | 2016-06-07 | 2017-12-14 | 江苏恒瑞医药股份有限公司 | 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用 |
WO2018103624A1 (zh) * | 2016-12-06 | 2018-06-14 | 江苏恒瑞医药股份有限公司 | 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途 |
Non-Patent Citations (8)
Title |
---|
ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 42, no. 39, 2003, pages 4793 - 4795 |
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, vol. 45, no. 28, 2006, pages 4641 - 4644 |
BIOORGANIC MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 9, 2007, pages 2448 - 2451 |
CHEMMEDCHEM, vol. 10, no. 7, 2015, pages 1232 - 1239 |
CUNHA TM ET AL., MOLECULAR PAIN, vol. 8, no. 1, 2012, pages 10 |
FUJITA-HAMABE ET AL., JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 62, no. 8, 2010, pages 995 - 1002 |
RONG LIU ET AL., CHINA PHARMACEUTICALS, vol. 25, no. 22, 2016, pages 41 - 44 |
See also references of EP3714882A4 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020147848A1 (zh) * | 2019-01-17 | 2020-07-23 | 上海海雁医药科技有限公司 | 三环取代的氧杂螺环衍生物、其制法与医药上的用途 |
CN113493490A (zh) * | 2020-04-03 | 2021-10-12 | 成都诺和晟泰生物科技有限公司 | 一种合成肽酰胺类化合物及其在医药领域的用途 |
CN113493490B (zh) * | 2020-04-03 | 2024-03-12 | 成都诺和晟泰生物科技有限公司 | 一种合成肽酰胺类化合物及其在医药领域的用途 |
US11492374B2 (en) | 2020-06-25 | 2022-11-08 | Humanwell Pharmaceutical US | Peptides for treatment of medical disorders |
CN113995733A (zh) * | 2021-09-18 | 2022-02-01 | 中国人民解放军军事科学院军事医学研究院 | 一种噻吩诺啡缓释药物组合物及其制备方法和其用途 |
CN113995733B (zh) * | 2021-09-18 | 2023-08-22 | 中国人民解放军军事科学院军事医学研究院 | 一种噻吩诺啡缓释药物组合物及其制备方法和其用途 |
CN115317453A (zh) * | 2022-09-01 | 2022-11-11 | 广东嘉博制药有限公司 | 一种缓释微球制剂及其制备方法与用途 |
Also Published As
Publication number | Publication date |
---|---|
CA3083028A1 (en) | 2019-06-13 |
BR112020010429A2 (pt) | 2020-11-24 |
TW201924681A (zh) | 2019-07-01 |
AU2018380173A1 (en) | 2020-05-21 |
US20200368309A1 (en) | 2020-11-26 |
JP2021505547A (ja) | 2021-02-18 |
CN111065390A (zh) | 2020-04-24 |
EP3714882A4 (en) | 2021-09-01 |
EP3714882A1 (en) | 2020-09-30 |
CN111065390B (zh) | 2023-01-24 |
RU2020115687A3 (zh) | 2022-01-31 |
MX2020005660A (es) | 2020-08-20 |
US11471503B2 (en) | 2022-10-18 |
KR20200096787A (ko) | 2020-08-13 |
RU2020115687A (ru) | 2022-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018188641A1 (zh) | 一种mor激动剂与kor激动剂的药物组合物及其用途 | |
WO2019109937A1 (zh) | Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途 | |
WO2020038415A1 (en) | Tropomyosin receptor kinase (trk) degradation compounds and methods of use | |
BR112021002327A2 (pt) | derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4,5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona e compostos relacionados como inibidores de ptpn11(shp2) para o tratamento do câncer | |
JPH05320162A (ja) | ペプチド性キヌクリジン | |
SK13952002A3 (sk) | Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén | |
TW200831086A (en) | Spirocyclic Azetidinone Compounds and methods of use thereof | |
WO2006016695A1 (ja) | Ep4アゴニストを含有してなる高カリウム血症の予防および/または治療剤 | |
CA2822453A1 (en) | Novel morphinans useful as analgesics | |
JP2024096834A (ja) | (s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸の合成法 | |
WO2021060453A1 (ja) | 架橋型光学活性2級アミン誘導体 | |
WO2014112898A1 (ru) | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16a | |
JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
CA2944211A1 (en) | Compositions and methods for treating neurodegenerative diseases | |
US20130338372A1 (en) | Substituted Imidazoline Compounds | |
RU2776842C2 (ru) | Применение агониста kor в комбинации с агонистом mor для получения лекарственного средства для лечения боли | |
JP2021525269A (ja) | 疼痛処置のための化合物、それを含む組成物及びそれを使用する方法 | |
JPH07509242A (ja) | 5−htアゴニストまたはアンタゴニストとしての1−アザアダマンタン誘導体 | |
JP2019535680A (ja) | キナーゼを阻害する組成物及び方法 | |
JP2019509321A (ja) | 疼痛を処置するための組み合わせ | |
CN107200725B (zh) | 稠杂环类衍生物、其制备方法及其在医药上的应用 | |
JP2006306738A (ja) | 神経因性疼痛治療剤 | |
WO2022246025A1 (en) | Inhibitors and degraders of pip4k protein | |
TW202430163A (zh) | 作為flt3抑制劑的新穎n-雜芳基苯甲醯胺衍生物 | |
TW200404064A (en) | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18885338 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3083028 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2018380173 Country of ref document: AU Date of ref document: 20181205 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020529356 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207018160 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018885338 Country of ref document: EP Effective date: 20200622 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2020115687 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020010429 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112020010429 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200525 |